Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen
NCT ID: NCT07215936
Last Updated: 2025-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
100 participants
INTERVENTIONAL
2025-09-25
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Therapeutic Effect of Different Doses of Capecitabine
NCT06246461
Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer
NCT00290966
Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status
NCT00733616
A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
NCT02563054
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
NCT06194981
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A :will receive capecitabine dose dense 1750 mg /m2 7days on treatment and 7 days off
Arm A:Dose_dense Capecitabine in Colorectal cancer
Appling dose \_dense Capecitabine 1750mg/m2 for one week then one week off Cycle repeated every 2 weeks
Arm B will receive capecitabine standard dose 1000mg/m2 2weeks on and 1 week off
Arm B : standard dose Capecitabine
Pateints will receive capecitabine 1000 mg/m2 for 2 weeks then one week off
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arm A:Dose_dense Capecitabine in Colorectal cancer
Appling dose \_dense Capecitabine 1750mg/m2 for one week then one week off Cycle repeated every 2 weeks
Arm B : standard dose Capecitabine
Pateints will receive capecitabine 1000 mg/m2 for 2 weeks then one week off
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aliaa Alaa Abdelrahman
Assisstant lectular of clinical oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag university hospital
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh_med_25_9___4MD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.